Background-landing
Research and Discovery
The pace of innovation in the field of nuclear medicine and molecular imaging is both exciting and challenging. Many new molecular imaging agents and therapies are showing great promise for helping patients who now have few options. Through its Clinical Trials Network, centers of excellence and councils, SNMMI is working at all stages of the process to support innovation, develop best practices and ensure that patients have access to new procedures of proven value.
SNMMI is developing a broad-based vision document outlining the roles of precision imaging and radiopharmaceutical therapy in cancer, neuroimaging, and other disease areas where there are unmet needs. This document will be the basis for further plans, which in turn will be supported by focused grant applications and fundraising.
Promoting research.
The society is working with the Value Initiative Industry Alliance to provide support for trials and with the Small Business Advisory Alliance to increase collaboration between industry and academia. Other efforts include conducting grant-writing courses, assisting academic sites with 68Ga-PSMA studies, broadening the uses for FDG to include infection and inflammation imaging, and working to bring non-proprietary agents, such as F-DOPA, to patients.
Expanding support for new agents and instrumentation.
Figure: A 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months. 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-choline PET/CT (B,D) was negative (arrows). Credit: A Piccardo et al., Galliera Hospital, Genoa, Italy
SNMMI is partnering with a variety of potential funding sources, including industry, foundations and the National Institutes of Health, to raise awareness of nuclear medicine and molecular imaging, including theranostics, and to encourage further allocation of appropriate funding in these areas.
Increasing funding for research.
The Journal of Nuclear Medicine editors are supporting this effort through an enhanced checklist for submitted articles to ensure that they can be used to document the efficacy and safety of new procedures. The society is also developing educational sessions and papers on study design, template protocols for common molecular imaging studies, and training materials on new radiopharmaceuticals for the nuclear medicine community and referring physicians.
Improving the quality of nuclear medicine trials and literature.
Poster authors discuss their research at the SNMMI Annual Meeting
SNMMI LogoValue Initiative logo